The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Hanauer, Stephen
One or more keywords matched the following items that are connected to Hanauer, Stephen
Item TypeName
Concept Administration, Oral
Academic Article Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A.
Academic Article Cyclosporin for severe ulcerative colitis: a user's guide.
Academic Article Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
Academic Article Efficacy of parenteral methotrexate in refractory Crohn's disease.
Academic Article Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
Academic Article Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Academic Article The state of the art in the management of inflammatory bowel disease.
Academic Article Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
Academic Article Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Academic Article Aminosalicylates: old and new.
Academic Article Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.
Academic Article Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Academic Article Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Academic Article Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
Academic Article Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.
Academic Article Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Academic Article Oral or Topical 5-ASA in Ulcerative Colitis.
Academic Article Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Search Criteria
  • Administration Oral